Sumo Group has announced it will be refocusing its business to cater "exclusively on development services for partners", ...

Cassava Sciences (SAVA)’ trial for simufilam 50 mg or 100 mg for mild-to-moderate Alzheimer’s disease, named “REFOCUS-ALZ,” has been ...

Verily, Alphabet Inc.'s health technology subsidiary, announced Thursday it will sell its stop-loss insurance business, ...

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials and associated activities, including the ongoing VIO-01 trial. This ...

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials and associated activities ...